How should facial palsy or marked asymmetry be assessed before filler?

A new, progressive or unexplained facial asymmetry needs medical assessment before it is treated as an aesthetic volume difference. Filler may be considered for selected contour goals in stable prior palsy, but it does not restore nerve function, cannot promise complete symmetry and must preserve function.

This translation has no recorded clinical or medical-language review.

Direct answer

Sudden facial droop with speech or limb symptoms requires emergency assessment.
Record resting asymmetry separately from movement during smile, eye closure and speech.
Filler does not treat nerve injury or replace diagnosis and rehabilitation.

Establish onset and cause first

Determine whether asymmetry is congenital, old and stable, or new. Ask about onset, progression, pain, numbness, hearing or visual symptoms, trauma, surgery, dental work, tumour history and prior facial-palsy treatment. Defer elective procedures with a new neurological finding. Even after diagnosis, coordination with neurology, ENT, ophthalmology or plastic surgery follow-up may be appropriate.

Static and dynamic measurement

Add functional images at rest, gentle and full smile, lip purse and eye closure to standardized frontal, oblique and profile photographs. Consider bone, fat, muscle, skin, teeth and jaw separately. Simply adding more volume to one side may create weight or a new imbalance during movement. Prior filler and surgical changes may warrant ultrasound in selected cases.

A limited goal and follow-up

Base the plan on a bounded outcome, such as softening a defined depression. Perfect symmetry is not a realistic natural-face goal. Choose product, plane and volume around function, support and vascular risk. A staged approach, baseline video and follow-up allow reassessment before adding volume. New weakness or a change in speech or eye closure needs urgent evaluation rather than automatic attribution to filler.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

Dermal Fillers (Soft Tissue Fillers)
U.S. Food and Drug Administration (FDA) · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Guideline for the Management of Hyaluronic Acid Filler-Induced Vascular Occlusion
Gillian Murray, Cormac Convery, Lee Walker, Emma Davies; Complications in Medical Aesthetics Collaborative (CMAC) · 2021
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review
Audra Janovskiene, Deividas Chomicius, Dominykas Afanasjevas, Zygimantas Petronis, Dainius Razukevicius, Egle Jagelaviciene · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Use of Ultrasound in the Management of Hyaluronic Acid Filler Complications: An International Delphi Consensus
International expert Delphi panel · 2025
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
BELOTERO VOLUME (+) Lidocaine — Instructions for Use
FDA device labeling / Merz North America · 2026
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review